| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4977138 | BRISTOL-MYERS | FR901228 substance and preparation thereof |
Aug, 2013
(10 years ago) | |
| US7611724 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(2 years ago) | |
| US7608280 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(2 years ago) | |
Istodax is owned by Bristol-Myers.
Istodax contains Romidepsin.
Istodax has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Istodax are:
- US4977138
- US7611724
- US7608280
Istodax was authorised for market use on 05 November, 2009.
Istodax is available in powder;intravenous dosage forms.
Drug patent challenges can be filed against Istodax from 05 November, 2013.
The generics of Istodax are possible to be released after 22 August, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-12) | Jun 16, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2014 |
| Orphan Drug Exclusivity(ODE) | Jun 16, 2018 |
Drugs and Companies using ROMIDEPSIN ingredient
NCE-1 date: 05 November, 2013
Market Authorisation Date: 05 November, 2009
Treatment: NA
Dosage: POWDER;INTRAVENOUS
How can I launch a generic of ISTODAX before it's drug patent expiration?
More Information on Dosage
ISTODAX family patents
